Recent research further demonstrates that antibody-T moiety-exatecan conjugates targeting HER2, HER3, and TROP-2 can effectively overcome both intrinsic and acquired resistance observed with equivalent DXd or SN-38-based ADCs, particularly in tumors characterized by low antigen expression, high tumor burden, or multidrug resistance. Here, ERBB2 is linked to neoplasm.